Matthew Taylor

Assistant Professor

  • 3518 Citations
  • 12 h-Index
20102019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2010 2019

  • 3518 Citations
  • 12 h-Index
  • 25 Article
  • 1 Comment/debate
2019
4 Citations (Scopus)

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial

Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 12.

Research output: Contribution to journalArticle

Melanoma
Neoplasms
Therapeutics
Disease-Free Survival
Survival

Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)

Berry, S., Giraldo, N., Nguyen, P., Green, B., Xu, H., Ogurtsova, A., Soni, A., Succaria, F., Wang, D., Roberts, C., Stein, J., Engle, E., Pardoll, D., Anders, R., Cottrell, T., Taube, J. M., Tran, B., Voskoboynik, M., Kuo, J., Bang, Y. L. & 72 others, Chung, H. C., Ahn, M. J., Kim, S. W., Perera, A., Freeman, D., Achour, I., Faggioni, R., Xiao, F., Ferte, C., Lemech, C., Meric-Bernstam, F., Werner, T., Hodi, S., Messersmith, W., Lewis, N., Talluto, C., Dostalek, M., Tao, A., McWhirter, S., Trujillo, D., Luke, J., Xu, C., Bomarelli, B., Qi, J., Qin, G., Yu, H., Jenkins, M., Lo, K. M., Halle, J. P., Lan, Y., Taylor, M., Vogelzang, N., Cohn, A., Stepan, D., Shumaker, R., Dutcus, C., Guo, M., Schmidt, E., Rasco, D., Brose, M., Di Simone, C., Jain, S., Richards, D., Encarnacion, C., Vogelzeng, N., Mier, J., An, J., Yang, Y. Y., Lee, W. H., Yang, J., Kim, J. K., Kim, H. G., Paek, S. H., Lee, J. W., Woo, J., Kim, J. B., Kwon, H., Lim, W., Paik, N. S., Kim, Y. K., Moon, B. I., Janku, F., Tan, D., Martin-Liberal, J., Takahashi, S., Geva, R., Gucalp, A., Chen, X., Subramanian, K., Mataraza, J., Wheler, J. & Bedard, P., Feb 13 2019, In : Journal for immunotherapy of cancer. 7, 1, 46.

Research output: Contribution to journalArticle

Open Access
Immunotherapy
Publications
Neoplasms
12 Citations (Scopus)

Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer: Phase 1b Results from the JAVELIN Solid Tumor Trial

Disis, M. L., Taylor, M., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., Hamilton, E. P., Annunziata, C. M., Grote, H. J., Von Heydebreck, A., Grewal, J., Chand, V. & Gulley, J. L., Jan 1 2019, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

Patient Safety
Ovarian Neoplasms
Neoplasms
avelumab
Platinum
8 Citations (Scopus)

Larotrectinib in adult patients with solid tumours: A multi-centre, open-label, phase i dose-escalation study

Hong, D. S., Bauer, T. M., Lee, J. J., Dowlati, A., Brose, M. S., Farago, A. F., Taylor, M., Shaw, A. T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B. B., Ebata, K., Cruickshank, S., Cox, M. C., Burris, H. A. & Doebele, R. C., Feb 1 2019, In : Annals of Oncology. 30, 2, p. 325-331 7 p.

Research output: Contribution to journalArticle

Open Access
Gene Fusion
Neoplasms
Maximum Tolerated Dose
Anemia
Appointments and Schedules
10 Citations (Scopus)

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., Schmidt, E. V., Guo, M., Sachdev, P., Shumaker, R., Aghajanian, C. & Taylor, M., May 1 2019, In : The Lancet Oncology. 20, 5, p. 711-718 8 p.

Research output: Contribution to journalArticle

Endometrial Neoplasms
Therapeutics
Hypothyroidism
Diarrhea
pembrolizumab
2018
105 Citations (Scopus)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K. W., Taylor, M., Schöffski, P., Wang, D., Ravaud, A., Gelb, A. B., Xiong, J., Rosen, G., Gulley, J. L. & Apolo, A. B., Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 51-64 14 p.

Research output: Contribution to journalArticle

Platinum
Carcinoma
Neoplasms
Safety
avelumab

Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients with Metastatic Melanoma

Murphy, B., Walker, J., Bassale, S., Monaco, D., Jaboin, J., Ciporen, J., Taylor, M. & Dai Kubicky, C., Jan 1 2018, (Accepted/In press) In : American Journal of Clinical Oncology: Cancer Clinical Trials.

Research output: Contribution to journalArticle

Radiosurgery
Melanoma
Immunotherapy
Disease-Free Survival
Survival
3 Citations (Scopus)

Efficacy and Safety of Avelumab Treatment in Patients with Advanced Unresectable Mesothelioma: Phase 1b Results from the JAVELIN Solid Tumor Trial

Hassan, R., Thomas, A., Nemunaitis, J. J., Patel, M. R., Bennouna, J., Chen, F. L., Delord, J. P., Dowlati, A., Kochuparambil, S. T., Taylor, M., Powderly, J. D., Vaishampayan, U. N., Verschraegen, C., Grote, H. J., Von Heydebreck, A., Chin, K. & Gulley, J. L., Jan 1 2018, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

Mesothelioma
Safety
Neoplasms
Cell Death
Pemetrexed
267 Citations (Scopus)

Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children

Drilon, A., Laetsch, T. W., Kummar, S., Dubois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V. & 18 others, Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. P. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S. & Hyman, D. M., Feb 22 2018, In : New England Journal of Medicine. 378, 8, p. 731-739 9 p.

Research output: Contribution to journalArticle

Neoplasms
Research Personnel
tropomyosin kinase
Confidence Intervals
Safety
11 Citations (Scopus)

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Gambacorti-Passerini, C., Orlov, S., Zhang, L., Braiteh, F., Huang, H., Esaki, T., Horibe, K., Ahn, J. S., Beck, J. T., Edenfield, W. J., Shi, Y., Taylor, M., Tamura, K., Van Tine, B. A., Wu, S. J., Paolini, J., Selaru, P. & Kim, T. M., Jan 1 2018, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Neoplasms
Lymphoma
Confidence Intervals
Safety
30 Citations (Scopus)

Precision targeted therapy with BLU-667 for RET-driven cancers

Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., Wilson, K. J., Dipietro, L., Fleming, P., Palmer, M., Hu, M. I., Wirth, L., Brose, M. S., Ou, S. H. I., Taylor, M., Garralda, E. & 5 others, Miller, S., Wolf, B., Lengauer, C., Guzi, T. & Evans, E. K., Jul 1 2018, In : Cancer Discovery. 8, 7, p. 836-849 14 p.

Research output: Contribution to journalArticle

Transfection
Neoplasms
Thyroid Neoplasms
Therapeutics
Non-Small Cell Lung Carcinoma
22 Citations (Scopus)

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Kelly, K., Infante, J. R., Taylor, M., Patel, M. R., Wong, D. J., Iannotti, N., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I. & Gulley, J. L., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Clinical Trials
Safety
Neoplasms
avelumab
CD274 Antigen
10 Citations (Scopus)

Signature program: A platform of basket trials

Slosberg, E. D., Kang, B. P., Peguero, J., Taylor, M., Bauer, T. M., Berry, D. A., Braiteh, F., Spira, A., Meric-Bernstam, F., Stein, S., Piha-Paul, S. A. & Salvado, A., Apr 20 2018, In : Oncotarget. 9, 30, p. 21383-21395 13 p.

Research output: Contribution to journalArticle

Neoplasms
Mutation
Hematologic Neoplasms
Clinical Studies
Therapeutics
2017

Academic cancer center phase i program development

Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J. A., Taylor, M., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P., Apr 1 2017, In : Oncologist. 22, 4, p. 369-374 6 p.

Research output: Contribution to journalComment/debate

Program Development
Neoplasms
Research
Research Personnel
Clinical Trials
9 Citations (Scopus)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Kiyota, N., Robinson, B., Shah, M., Hoff, A. O., Taylor, M., Li, D., Dutcus, C. E., Lee, E. K., Kim, S. B. & Tahara, M., Sep 1 2017, In : Thyroid : official journal of the American Thyroid Association. 27, 9, p. 1135-1141 7 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Safety
Placebos
Confidence Intervals
Disease Progression
38 Citations (Scopus)

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors

Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M., Northfelt, D. W., Carson, W. E., Hawthorne, T. R., Davis, T. A., Yellin, M. J., Keler, T. & Bullock, T., Jun 20 2017, In : Journal of Clinical Oncology. 35, 18, p. 2028-2036 9 p.

Research output: Contribution to journalArticle

Anti-Idiotypic Antibodies
Safety
Neoplasms
T-Lymphocytes
Disease-Free Survival
2016
19 Citations (Scopus)

Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer

Robinson, B., Schlumberger, M., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M., Kim, S. B., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I. & Tahara, M., Nov 1 2016, In : Journal of Clinical Endocrinology and Metabolism. 101, 11, p. 4103-4109 7 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Tumors
Neoplasms
Disease-Free Survival
Placebos
354 Citations (Scopus)

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D. R., Salama, A. K., Taylor, M., Ott, P. A., Horak, C., Gagnier, P., Jiang, J., Wolchok, J. D. & 1 others, Postow, M. A., Nov 1 2016, In : The Lancet Oncology. 17, 11, p. 1558-1568 11 p.

Research output: Contribution to journalArticle

Melanoma
Survival
nivolumab
ipilimumab
Colitis
420 Citations (Scopus)

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., Morse, M. A., Ascierto, P. A., Horn, L., Amin, A., Pillai, R. N., Evans, J., Chau, I., Bono, P., Atmaca, A., Sharma, P. & 4 others, Harbison, C. T., Lin, C. S., Christensen, O. & Calvo, E., 2016, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
nivolumab
ipilimumab
Therapeutics
Platinum
10 Citations (Scopus)

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Graff, J., Higano, C. S., Hahn, N. M., Taylor, M., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J. & Sarantopoulos, J., Aug 15 2016, In : Cancer. 122, 16, p. 2524-2533 10 p.

Research output: Contribution to journalArticle

docetaxel
Aurora Kinase A
Neoplasms
Pharmacokinetics
Fever
3 Citations (Scopus)

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

Gianoukakis, A. G., Flores, N. M., Pelletier, C. L., Forsythe, A., Wolfe, G. R. & Taylor, M., May 30 2016, In : Cancer Management and Research. 8, p. 67-76 10 p.

Research output: Contribution to journalArticle

Patient Acceptance of Health Care
Health Resources
Thyroid Neoplasms
Iodine
Health
2015
41 Citations (Scopus)

Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers

Naugler, W. S., Tarlow, B. D., Fedorov, L., Taylor, M., Pelz, C., Li, B., Darnell, J. & Grompe, M., Sep 1 2015, In : Gastroenterology. 149, 3, p. 728e15-740e15

Research output: Contribution to journalArticle

Fibroblast Growth Factors
Bile Acids and Salts
Liver
Hepatocytes
Body Weight
446 Citations (Scopus)

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer

Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., Gianoukakis, A. G., Kiyota, N., Taylor, M., Kim, S. B., Krzyzanowska, M. K., Dutcus, C. E., De Las Heras, B., Zhu, J. & Sherman, S. I., Feb 12 2015, In : New England Journal of Medicine. 372, 7, p. 621-630 10 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Placebos
Iodine
Disease-Free Survival
Survival Rate
1429 Citations (Scopus)

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D. & 1 others, Hodi, F. S., May 21 2015, In : New England Journal of Medicine. 372, 21, p. 2006-2017 12 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Poisons
nivolumab
ipilimumab
2014
7 Citations (Scopus)

Medical Therapy for Advanced Forms of Thyroid Cancer

Rajhbeharrysingh, U., Taylor, M. & Milas, K., 2014, In : Surgical Clinics of North America. 94, 3, p. 541-571 31 p.

Research output: Contribution to journalArticle

Local Neoplasm Recurrences
Molecular Targeted Therapy
Adjuvant Radiotherapy
Thyroid Neoplasms
Antineoplastic Agents
2010
260 Citations (Scopus)

The ploidy conveyor of mature hepatocytes as a source of genetic variation

Duncan, A. W., Taylor, M., Hickey, R. D., Hanlon Newell, A. E., Lenzi, M. L., Olson, S., Finegold, M. J. & Grompe, M., Oct 7 2010, In : Nature. 467, 7316, p. 707-710 4 p.

Research output: Contribution to journalArticle

Ploidies
Hepatocytes
Polyploidy
Chromosomes
Artificial Cells